NEURODIAGNOSTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

The global neurodiagnostics market is estimated to be valued at USD 8.66 Bn in 2024 and is expected to exhibit a CAGR of 8.1% during the forecast period (2024-2031). Neurodiagnostics refers to the diagnosis of neurological disorders through various imaging and monitoring techniques. It involves the evaluation of the central and peripheral nervous system for any abnormalities. The neurodiagnostics market has been witnessing significant growth over the past few years due to the rising incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and various cancers affecting the nervous system. Advancements in neuroimaging technologies and development of novel biomarkers have enabled the early and accurate diagnosis of these conditions. Furthermore, the growing geriatric population who are more susceptible to neurological diseases, increasing healthcare expenditures, and availability of reimbursement are some of the key factors expected to drive the demand for neurodiagnostics in the coming years

Market Dynamics:

The global neurodiagnostics market is primarily driven by the rising prevalence of neurological disorders worldwide. According to the World Health Organization (WHO), over 1 billion people suffer from neurological disorders globally with neurological and mental disorders accounting for nearly 10% of the global disease burden. The market is also being propelled by the development of advanced neurodiagnostic technologies such as magnetic resonance imaging, ultrasound scanners, computed tomography scanners, and positron emission tomography (PET) scanners which provide high resolution images and aid accurate evaluation of neurological structures and functions. However, the market growth can be restrained by the high cost of innovative neurodiagnostic devices and procedures. On the positive side, growing healthcare investment in emerging nations presents lucrative opportunities for market players. Intensifying R&D in the fields of pharmacogenetics and personalized medicine also bodes well for the market expansion over the forecast period.

Key Features of the Study:

• This report provides an in-depth analysis of the global neurodiagnostics market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global neurodiagnostics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Koninklijke Philips N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro, NEUROLITE AG, and Atlantic Health System.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global neurodiagnostics market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurodiagnostics market.

Detailed Segmentation-

• By Product Type:
  • Electroencephalogram (EEG) Systems
  • Magnetic Resonance Imaging (MRI) Systems
  • Ultrasound Imaging Systems
  • Computed Tomography (CT) Scanner
  • Reagents & Consumables
  • Others
• By Therapeutic Area:
  • Neurodegenerative Diseases
  • Sleep Disorders
  • Stroke
  • Epilepsy
  • Others
• By End User:
  • Hospitals
  • Diagnostic Centers
  • Ambulatory Care Centers
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Koninklijke Philips N.V
  • Siemens Healthcare GmbH
  • Hoffmann-La Roche Ltd
  • FUJIFILM Holdings Corporation
  • Bio-Rad Laboratories Inc.
  • Advanced Brain Monitoring, Inc.
  • Nihon Kohden Corporation
  • Mitsar Co. LTD.
  • EMS Biomedical
  • Mennen Medical
  • Natus Medical Incorporated
  • Medicaid Systems
  • Fujirebio 
  • FONAR Corp
  • ANT Neuro
  • NEUROLITE AG 
  • Atlantic Health System